ArticleClinical pharmacology and therapeutics2019

Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis.

Gerard Bruin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.